Wolfe Research Increases Insulet (NASDAQ:PODD) Price Target to $375.00

Insulet (NASDAQ:PODD) had its price target upped by research analysts at Wolfe Research from $350.00 to $375.00 in a report released on Friday,MarketScreener reports. The brokerage presently has an “outperform” rating on the medical instruments supplier’s stock. Wolfe Research’s price target would indicate a potential upside of 15.27% from the company’s current price.

Several other research analysts have also recently weighed in on PODD. Canaccord Genuity Group upped their price target on shares of Insulet from $353.00 to $399.00 and gave the stock a “buy” rating in a report on Monday, September 29th. Stifel Nicolaus assumed coverage on Insulet in a research report on Tuesday, October 21st. They set a “buy” rating and a $370.00 target price for the company. The Goldman Sachs Group lowered their price target on Insulet from $399.00 to $375.00 and set a “buy” rating on the stock in a report on Wednesday, October 1st. Weiss Ratings reissued a “hold (c)” rating on shares of Insulet in a report on Wednesday, October 8th. Finally, Morgan Stanley restated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average price target of $367.74.

Insulet Price Performance

Shares of Insulet stock traded up $1.93 on Friday, reaching $325.33. The stock had a trading volume of 68,467 shares, compared to its average volume of 718,270. The business’s 50 day moving average is $325.46 and its two-hundred day moving average is $308.84. The company has a current ratio of 2.26, a quick ratio of 1.81 and a debt-to-equity ratio of 0.64. Insulet has a 1 year low of $230.05 and a 1 year high of $353.50. The company has a market cap of $22.90 billion, a P/E ratio of 99.11, a price-to-earnings-growth ratio of 2.64 and a beta of 1.39.

Insulet (NASDAQ:PODD) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $1.24 earnings per share for the quarter, topping analysts’ consensus estimates of $1.13 by $0.11. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $521.70 million for the quarter, compared to analyst estimates of $678.70 million. During the same quarter in the prior year, the firm posted $1.08 EPS. Insulet’s revenue was up 29.9% on a year-over-year basis. Insulet has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. As a group, research analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insider Activity at Insulet

In other news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total transaction of $278,001.57. Following the completion of the sale, the senior vice president owned 3,890 shares of the company’s stock, valued at approximately $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Prem Singh sold 687 shares of the firm’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the transaction, the senior vice president owned 3,456 shares in the company, valued at $1,200,925.44. This represents a 16.58% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.39% of the stock is owned by company insiders.

Institutional Investors Weigh In On Insulet

Institutional investors have recently added to or reduced their stakes in the company. Sage Mountain Advisors LLC increased its position in shares of Insulet by 4.6% in the third quarter. Sage Mountain Advisors LLC now owns 743 shares of the medical instruments supplier’s stock valued at $229,000 after acquiring an additional 33 shares during the period. Curi Capital LLC boosted its holdings in shares of Insulet by 0.8% during the second quarter. Curi Capital LLC now owns 4,346 shares of the medical instruments supplier’s stock worth $1,365,000 after purchasing an additional 36 shares during the period. Evelyn Partners Investment Management Services Ltd grew its stake in shares of Insulet by 28.7% in the second quarter. Evelyn Partners Investment Management Services Ltd now owns 175 shares of the medical instruments supplier’s stock worth $55,000 after purchasing an additional 39 shares during the last quarter. PDS Planning Inc increased its holdings in Insulet by 5.1% during the 3rd quarter. PDS Planning Inc now owns 821 shares of the medical instruments supplier’s stock valued at $253,000 after purchasing an additional 40 shares during the period. Finally, Camarda Financial Advisors LLC raised its position in Insulet by 0.5% during the 2nd quarter. Camarda Financial Advisors LLC now owns 7,332 shares of the medical instruments supplier’s stock valued at $2,304,000 after purchasing an additional 40 shares during the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.